Purified Hematopoietic Stem Cell Transplantation: The Next Generation of Blood and Immune Replacement

Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, 279 Campus Drive, Stanford, CA 94305, USA
Immunology and Allergy Clinics of North America (Impact Factor: 1.82). 05/2010; 30(2):159–171. DOI: 10.1016/j.iac.2010.03.003


Replacement of disease-causing stem cells with healthy ones has been achieved clinically via hematopoietic cell transplantation (HOT) for the last 40 years, as a treatment modality for a variety of cancers and immunodeficiencies with moderate, but increasing, success. This procedure has traditionally included transplantation of mixed hematopoietic populations that include hematopoietic stem cells (HSC) and other cells, such as T cells. This article explores and delineates the potential expansion of this technique to treat a variety of inherited diseases of immune function, the current barriers in HOT and pure HSC transplantation, and the up-and-coming strategies to combat these obstacles.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Notch is a crucial cell signaling pathway in metazoan development. By means of cell-cell interactions, Notch signaling regulates cellular identity, proliferation, differentiation and apoptosis. Within the last decade, numerous studies have shown an important role for this pathway in the development and homeostasis of mammalian stem cell populations. Hematopoietic stem cells (HSCs) constitute a well-defined population that shows self-renewal and multi-lineage differentiation potential, with the clinically relevant capacity to repopulate the hematopoietic system of an adult organism. Here, we review the emergence, development and maintenance of HSCs during mammalian embryogenesis and adulthood, with respect to the role of Notch signaling in hematopoietic biology.
    Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 06/2011; 25(10):1525-32. DOI:10.1038/leu.2011.127 · 10.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Stem cells have enormous potential to revolutionise the drug discovery process at all stages, from target identification through to toxicology studies. Their ability to generate physiologically relevant cells in limitless supply makes them an attractive alternative to currently used recombinant cell lines or primary cells. However, realisation of the full potential of stem cells is currently hampered by the difficulty in routinely directing stem cell differentiation to reproducibly and cost effectively generate pure populations of specific cell types. In this article we discuss how stem cells have already been used in the drug discovery process and how novel technologies, particularly in relation to stem cell differentiation, can be applied to attain widespread adoption of stem cell technology by the pharmaceutical industry.
    Drug discovery today 11/2011; 17(7-8):336-42. DOI:10.1016/j.drudis.2011.11.001 · 6.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 are members of a discrete family of cytokines that regulates the growth, differentiation, migration and effector function activities of many hematopoietic cells and immunocytes. These cytokines are involved in normal responses to infectious agents, bridging innate and adaptive immunity. However, in certain cases, the overexpression of these cytokines or their receptors can lead to excessive or aberrant initiation of signaling resulting in pathological conditions, with chronic inflammatory diseases and myeloid leukemias the most notable examples. Recent crystal structures of the GM-CSF receptor ternary complex and the IL-5 binary complex have revealed new paradigms of cytokine receptor activation. Together with a wealth of associated structure-function studies, they have significantly enhanced our understanding of how these receptors recognize cytokines and initiate signals across cell membranes. Importantly, these structures provide opportunities for structure-based approaches for the discovery of novel and disease-specific therapeutics. In addition, recent biochemical evidence has suggested that the GM-CSF/IL-3/IL-5 receptor family is capable of interacting productively with other membrane proteins at the cell surface. Such interactions may afford additional or unique biological activities and might be harnessed for selective modulation of the function of these receptors in disease.
    Immunological Reviews 11/2012; 250(1):277-302. DOI:10.1111/j.1600-065X.2012.01164.x · 10.12 Impact Factor
Show more